A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

Metastatic Castration Resistant Prostate Cancer Clinical Trial

Official title:

A Phase I Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients With Metastatic Castration-Resistant Prostate Cancer.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03774056
• Other study ID #: HC-1119-01
• Status: Completed
• Phase: Phase 1
• Start date: February 10, 2017
• Est. completion date: August 28, 2019

Study information

• Verified date: October 2020
• Source: Hinova Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy of HC-1119 in patients with metastatic castration-resistant prostate cancer. The study objective is to study the tolerability, safety, and dose-limiting toxicities (DLT) of HC-1119 in patients with mCRPC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: August 28, 2019
• Est. primary completion date: September 26, 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria (those who meet all of the following are eligible):

1. Voluntarily participated in the study, with understanding of relevant study procedures and signed informed consent form;

2. Male , =18 years old;

3. With histologically or cytologically confirmed prostate cancer, without neuroendocrine carcinoma or ductal adenocarcinoma;

4. With evidence of metastatic disease (such as bone scan and CT/MRI results);

5. Patients with relapsed, refractory, or progressive disease despite castration (surgery or chemical) or combined androgen deprivation therapy (Progressive disease is defined as 1 or more of the following 3 criteria: Serum PSA progression: A minimum of 3 rising PSA values with an interval of at least 1 week between determinations, resulting in a final value higher than 50% of the minimum, with a starting PSA value > 2 ng/ml; Soft tissue disease progression as defined by RECIST 1.1; Bone disease progression defined by PCWG2 with 2 or more new metastatic lesions on bone scan);

6. Castrate levels of testosterone (< 50 ng/dl) at screening;

7. Bilateral orchiectomy or ongoing androgen deprivation therapy with effective GnRH analogues;

8. Estimated life expectancy > 6 months;

9. ECOG performance status = 1;

10. Laboratory tests must meet the following criteria:

1. Routine Blood Test: hemoglobin (Hb) = 90 g/L (no blood transfusion within the last 14 days); absolute neutrophil count (ANC) = 1.5 x 109/L; platelet count (PLT) = 80 x 109/L;

2. Blood Biochemistry: creatinine (Cr) = 2 x upper limit of normal (ULN), or Cr > 2 x ULN but the calculated CrCl = 60 mL/min; bilirubin (BIL) = 2 x ULN; alanine aminotransferase (ALT), aspartate aminotransferase (AST) = 2.5 x ULN (or = 5.0 x ULN for patients with liver metastases);

3. Coagulation: INR < 1.5.

Exclusion Criteria (those who meet any one of the following are ineligible):

1. Ongoing toxicity ( = Grade 2 toxicity) from previous treatments;

2. Clinically significant GI dysfunction which may affect the intake, transport, or absorption of drug (such as inability to swallow, chronic diarrhea, and bowel obstruction, etc.), or patients with complete gastrectomy;

3. History of allergies, or known hypersensitivity to components of the investigational drug;

4. Brain metastases;

5. Other malignancies within the last 5 years (except for curatively treated non-melanoma skin cancer);

6. History of organ transplants

7. HIV seropositive;

8. Past medical history of seizures or serious CNS diseases;

9. History of unexplained coma;

10. Family history of seizures;

11. History of traumatic brain injury;

12. History of medication or drug abuse;

13. Patients with severe cardiovascular diseases, including those with myocardial infarction, arterial thrombosis, unstable angina, or clinical symptomatic heart failure within the past 6 months;

14. Uncontrolled hypertension (systolic = 160 mmHg or diastolic = 100 mmHg). Patients with a history of hypertension is eligible if his blood pressure is controlled with antihypertensives;

15. Medications that lower the seizure threshold must be used during the study;

16. Treatment with 5a-reductase inhibitors (finasteride, dutasteride), estrogen, or cyproterone within the past 4 weeks;

17. Treatment with ketoconazole within the past 4 weeks;

18. Previously treated with investigational or approved medications that inhibit testosterone synthesis (such as abiraterone acetate, TAK-683, and TAK-448) or target testosterone receptors (such as enzalutamide, SHR3680, proxalutamide, and ARN509);

19. Participated in other clinical trials within 1 month prior to enrollment;

20. Subjects is determined by the investigator to be unsuitable for this study.

Related Conditions & MeSH terms

• Metastatic Castration Resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• HC-1119
oral

Locations

Country	Name	City	State
China	Hinova Pharmaceuticals Inc.	Chengdu	Sichuan

Sponsors (2)

Lead Sponsor	Collaborator
Hinova Pharmaceuticals Inc.	West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicities(DLT)	Safety measures	From the first dose of the study to the 12th week after dose
Primary	Number of patients with adverse events	Safety measures	From the first dose of the study to the 12th week after dose
Secondary	Maximum drug concentration(Cmax)	Single-dose and repeated-dose	From the first dose of the study to the 12th week after dose
Secondary	Time of maximum drug concentration(Tmax)	Single-dose and repeated-dose	From the first dose of the study to the 12th week after dose
Secondary	Area under curve from time 0 to 24h (AUC0-24h)	Single-dose and repeated-dose	From the first dose of the study to the 12th week after dose
Secondary	Maximal PSA Response Rate	Percentage of patients with > 50% decrease in PSA levels from baseline during the 12-week treatment period	From the first dose of the study to the 12th week after dose
Secondary	Response rate of prostate specific antigen (PSA)	Percentage of patients with > 50% decrease in PSA levels from baseline at weeks 6, 8, 10, and 12.	From the first dose of the study to the 12th week after dose